Answers are grounded in this paper and cite their sources.
Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor, has demonstrated promising efficacy in B-cell malignancies and is associated with low rates of discontinuation and dose reduction. Pirtobrutinib is administered until disease progression or toxicity, necessitating an understanding of the safety profile in patients with extended treatment.
No takes yet. Share an insight, caveat, or question.
Roeker et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: